News Release

Mallinckrodt plc to Provide Business Update, Fiscal Year 2016 Financial Guidance and Historical Financial Information Excluding Contrast Media and Delivery Systems (CMDS)

-- Company to Hold an Investor Call on Tuesday, October 6, at 7:30 a.m. U.S. EDT --

CHESTERFIELD, United Kingdom, Oct. 5, 2015 /PRNewswire/ -- Mallinckrodt plc  (NYSE: MNK), a leading specialty biopharmaceutical company, announced that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6, 2015.

Mallinckrodt will also provide recast historical financial information reflecting the reclassification of its CMDS business to discontinued operations. The company announced plans to sell its CMDS business to Guerbet in late July 2015, with a closing expected in the first quarter fiscal 2016.

The investor call and question and answer session will take place on Tuesday, October 6, 2015, beginning at 7:30 a.m. U.S. Eastern Time. The call can be accessed:

  • On Mallinckrodt's website:
  • By telephone: The telephone dial-in number in the U.S. is (877) 359-9508. For participants outside the U.S., the dial-in number is (224) 357-2393; all callers should use the access code 55504186.
  • Through audio replay: A replay of the presentation will be available at 10:30 a.m. U.S. Eastern Time on October 6, 2015, and ending at 11:59 p.m. U.S. Eastern Time on October 20, 2015. The replay dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay conference I.D. for the investor call is 55504186. The replay may also be accessed on
  • The recast historical financial information will be posted in the Investor Relations section of the company's website.

Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops,
manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. To learn more about Mallinckrodt, visit


Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

Rhonda Sciarra
Communications Manager

Meredith Fischer
Senior Vice President, Communications and Public Affairs

To view the original version on PR Newswire, visit:

SOURCE Mallinckrodt plc